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Abstract: Ceftaroline is a novel broad-spectrum cephalosporin β-lactam antibiotic with activ-
ity against methicillin-resistant Staphylococcus aureus (MRSA) as well as multidrug-resistant 
Streptococcus pneumoniae among other routine Gram positive and Gram negative organisms. 
It has been approved by the US Food and Drug Administration for treatment of community-
acquired bacterial pneumonia and acute bacterial skin and skin structure infections (ABSSSIs). 
Ceftaroline is approved for treatment of ABSSSI due to MRSA, however currently there are 
no data for pneumonia due to MRSA in humans. Herein we review the major clinical trials as 
well as ceftaroline microbiology, pharmacokinetics, and safety, followed by a look at further 
directions for investigation of this new agent.
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Introduction to clinical applications of ceftaroline
Ceftaroline fosamil (formerly T-91825) is the N-phosphorylated prodrug of ceftaroline 
(formerly PPI 0903M and TAK-499), a novel broad spectrum β-lactam antibiotic with 
activity against methicillin-resistant Staphylococcus aureus (MRSA) as well as Strep-
tococcus pneumoniae with resistance to penicillin and other cephalosporins.1–3 Based 
on two Phase III studies in community-acquired bacterial pneumonia (CABP)4,5 and 
two Phase III studies in acute bacterial skin and skin structure infections (ABSSSIs),6,7 
ceftaroline received approval from the US Food and Drug Administration in 2010 for 
treatment of CAPB due to S. pneumoniae (including cases with concurrent bacteremia), 
methicillin-sensitive S. aureus (MSSA), Haemophilus influenzae, H. parainfluenzae, 
Klebsiella pneumoniae, and Escherichia coli as well as ABSSSI due to MSSA, 
MRSA, S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, Enterococcus 
faecalis (ampicillin-susceptible isolates only), E. coli, K. pneumoniae, K. oxytoca, and 
  Morganella morganii. This article will discuss the trials resulting in this approval in 
further depth, as well as the mode of action, microbiology, pharmacokinetics, and 
safety and tolerability of ceftaroline, as well as advantages and disadvantages in 
comparison to alternate therapies.
Clinical issues in the management  
of CABP and ABSSSI
Community-acquired bacterial pneumonia
The FOCUS (ceFtarOline Community-acquired pneUmonia trial vS ceftriaxone in 
hospitalized patients) trials are two Phase III multicenter, randomized, double-blind 
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trials comparing ceftaroline to ceftriaxone in CABP to 
demonstrate noninferiority.4,5,8 Patients with CAPB with 
Pneumonia Outcomes Research Team (PORT) scores of III 
or IV were randomized to receive either ceftaroline 600 mg 
intravenously (IV) every 12 hours or ceftriaxone 1 g IV every 
24 hours. Patients enrolled in either arm of FOCUS 1 also 
received two doses of clarithromycin 500 mg orally in the 
first 24 hours. Treatment was given for 5 to 7 days. Exclusion 
criteria included PORT class I, II, or V; intensive care unit 
admission at baseline; CABP suitable for outpatient therapy; 
confirmed or suspected health care-associated pneumonia 
pathogen; infection with a pathogen known to be resistant to 
study medication or high risk for such; high risk for MRSA 
or with Gram-positive cocci in clusters on sputum Gram 
stain; infection due to atypical pathogen (Legionella, Myco-
plasma, Chlamydophila spp.); prior antimicrobial therapy 
within 96 hours; creatinine clearance # 30 mL/min; elevated 
transaminases or bilirubin or other manifestation of end-stage 
liver disease; neutropenia or thrombocytopenia; empyema; 
and immunocompromise (chronic steroids, acquired immu-
nodeficiency syndrome, etc). The primary outcome was to 
determine noninferiority in clinical cure rates at a test-of-cure 
visit 8–15 days post therapy in the clinically evaluable and 
modified intention-to-treat (MITT) groups. Secondary out-
comes included cure in microbiologically evaluable (ME) and 
microbiological modified intention-to-treat (mMITT) groups 
(meaning at least one pathogen was isolated), cure at end of 
therapy, microbiological outcome at test-of-cure visit, overall 
success rate at test-of-cure visit, clinical and microbiological 
response by pathogen at test-of-cure visit, clinical relapse 
at a late follow-up visit (21–35 days after discontinuing 
study drug), microbiological reinfection/recurrence, and 
safety. A total of 1240 patients were randomized of whom 
1228 received any drug. 614 each received ceftaroline and 
  ceftriaxone. The two groups were similar in terms of baseline 
demographics, severity of pneumonia, comorbidities, and 
prior antibiotic use.
The clinical cure rate in the evaluable population was 
84.3% in the ceftaroline group versus 77.7% in the ceftriax-
one group (difference 6.7%, 95% confidence interval [CI]: 
1.6%–11.8%). In the MITT group, cure rates were 82.6% and 
76.6%, respectively (difference 6%, 95% CI: 1.4%–10.7%). 
For ME patients, cure rates were 85.1% versus 75.5% (differ-
ence 9.7, 95% CI: 0.7%–18.8%), and in the mMITT popula-
tion, cure rates were 83.6% versus 75% (difference 8.7%, 
95% CI: 0%–17.4%). All of these rates met noninferiority 
criteria, and all save the mMITT group reached numerical 
significance for the superiority of ceftaroline. For patients 
with S. pneumoniae infection, the cure rate for ceftaroline was 
85.5% compared with 68.6% with ceftriaxone (difference 
16.9%, no CI reported). For those with S. aureus infection 
including one patient with MRSA in the ceftriaxone arm, 
the cure rate was 72% versus 60% (difference 12%, no CI 
reported). In bacteremic patients, cure rates were 71.4% for 
ceftaroline compared with 58.8% for ceftriaxone (difference 
12.6%, 95% CI: –17.6%–41.6%).
Acute bacterial skin and skin 
structure infections
In 2007, a Phase II randomized, observer-blinded trial of 
ceftaroline compared with vancomycin with or without 
aztreonam for ABSSSI was released.9 The primary   outcome 
of this study was clinical cure rate at a test-of-cure visit; a 
blinded investigator determined cure as resolution of signs and 
symptoms of ABSSSI or improvement such that no further 
therapy was needed. This trial included 100 patients, 67 in 
the ceftaroline arm and 33 in the comparator arm. Those on 
ceftaroline received 600 mg IV every 12 hours.   Vancomycin 
was dosed at 1 g every 12 hours and   aztreonam at 1 g every 
8 hours. Patients were excluded if they had   creatinine 
clearance # 30 mL/min, .24 hours of antimicrobials in 
the preceding 96 hours, known vancomycin- or aztreonam-
resistant pathogens including Pseudomonas aeruginosa or 
anaerobes, underlying osteomyelitis or septic arthritis, necro-
tizing fasciitis, human or animal bites, diabetic foot ulcers, 
gangrene, burns covering .5% of the body, mediastinitis, 
or required surgical intervention that could not be performed 
within 48 hours of initiating therapy. The two groups were 
similar in baseline demographics, types of infection, and 
microbes isolated. Cure rates in evaluable patients in both 
arms were comparable.
This  study  was  followed  by  the  two  CANVAS 
 ( CeftAroliNe Versus VAncomycin in Skin and Skin 
Structure Infections) trials, Phase III multicenter, random-
ized, double blind studies again comparing ceftaroline to 
vancomycin with aztreonam for ABSSSI to demonstrate 
noninferiority.6,7,10 In these identical trials patients with 
ABSSSI were randomized to receive ceftaroline 600 mg IV 
every 12 hours plus normal saline placebo or vancomycin 
1 g every 12 hours with 1 g of aztreonam every 8 hours. 
Treatment was given for an average of 8 days. The primary 
outcome of these studies was clinical cure rate at test-of-
cure visit in clinically evaluable and MITT populations. 
Secondary outcomes were microbiological response and 
clinical response at a test-of-cure visit at 8–15 days after 
the last dose of study drug and relapse/reinfection at a late 
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follow up visit at 21–35 days after the last dose. Of 1396 
randomized patients, 1378 received at least one dose 
of study drug; 1202 were clinically evaluable, and 914 
were ME. The two groups were similar in demographic 
and infection data including sites of infection and area of 
involvement. In ME patients, S. aureus (MRSA and MSSA) 
was the most common pathogen.
The clinical cure rates in the evaluable groups were 
91.6% for ceftaroline and 92.7% for vancomycin plus 
aztreonam (difference −1.1%, 95% CI: −4.2%–2%); in the 
MITT group the cure rates were 85.9% and 85.5%, respec-
tively   (difference 0.3%, 95% CI: −3.4%–4%). Cure rates 
were also comparable in ME patients, 92.7% versus 94.4% 
(difference −1.7%, 95% CI: −4.9%–1.6%). In bacteremic 
patients, cure rates were 84.6% in the ceftaroline group 
versus 100% in the vancomycin plus aztreonam group (dif-
ference −15.4%, 95% CI: −33.8%–1.5%). This difference 
was not statistically significant. Of note there was a higher 
rate of S. aureus bacteremia (both MRSA and MSSA) in the 
ceftaroline group (18 vs 9).
Ceftaroline: mode of action, 
microbiology, pharmacokinetics, 
safety, and tolerability
Mode of action
As with other β-lactam antibiotics, ceftaroline acts by binding 
penicillin-binding proteins (PBP) on the bacterial cell wall 
leading to perturbations in new wall formation as well as cell 
lysis.1 These PBPs have a variety of structures and functions 
and different bacteria have different PBPs.11 Ceftaroline was 
demonstrated after initial synthesis to have strong affinity 
for PBP 2a, a genetically altered PBP in MRSA.1 Further 
in vitro research has again demonstrated strong affinity for 
PBP 2a-conferring activity against MRSA, as well as a high 
affinity for PBPs 1a, 2b, 2x, and 3, which are important 
PBPs in MSSA and S. pneumoniae.12,13 These binding 
affinities were notably higher than those for oxacillin and 
ceftriaxone, standard antimicrobials for treatment of MSSA 
and S.   pneumoniae, respectively.
Microbiology
Ceftaroline has a broad spectrum of activity which is rep-
resented in Table 1. Early in vitro testing demonstrated 
favorable minimum inhibitory concentration (MIC) 
against S. aureus, both MRSA and MSSA; S. epidermidis 
(methicillin-sensitive and -resistant strains); S. pneumoniae, 
including penicillin-resistant strains; and other streptococci. 
Table 1   MIC  ranges  and  MIC50–90  against  selected   
pathogens.2,3,16–18,20–29,33,34
Organism MIC Range MIC50 MIC90
MSSA #0.008–1 0.12–0.25 0.25–0.5
MRSA 0.12–4 0.5–1 0.5–2
CONS #0.008–4 0.06–1 0.12–2
PSSP #0.008–0.25 #0.008–0.015 #0.016–0.06
PISP #0.008–0.5 0.015–0.13 0.006–0.13
PRSP #0.008–0.5 #0.015–0.13 0.12–0.5
β-hemolytic  
streptococci
#0.008–0.12 #0.008–0.015 #0.015–0.03
viridans group  
streptococci
#0.008–16 #0.008–0.25 0.03–1
Enterococcus  
faecalisa
0.03–.32 1–4 4–16
Enterococcus  
faeciuma
0.06–.128 1–.64 16–.128
Acinetobacter spp #0.003–.64 2–.64 8–.64
Citrobacter  
freundii
0.06–128 0.12–.16 2–64
Enterobacter sppb #0.008–.128 #0.12–.32 0.5–.32
Escherichia colib #0.008–.64 0.06–.32 0.12–.32
Klebsiella sppb #0.008–.32 0.06–.32 0.25–.32
Proteus spp #0.03–.32 0.06–.32 0.12–64
Salmonella spp 0.06–.32 0.12–0.13 0.25–.32
Haemophilus  
influenzaec
#0.008–0.25 #0.008–0.12 #0.008–0.25
Moraxella  
catarrhalis
#0.008–1 0.03–0.25 0.12–0.5
Pseudomonas  
aeruginosa
0.25–.128 16 .32
Serratia marcescens 0.015–.128 0.5–1 2–32
Bacteroides spp 0.03–.64 8–64 16–.64
Clostridium spp #0.008–64 0.06–2 0.25–16
Fusobacterium sppd #0.008–64 #0.008–8 0.06–32
Propionibacterium  
acnes
#0.008–0.125 #0.008–0.03 0.06
Notes:  aIncludes vancomycin-susceptible and -resistant strains;  bincludes cephalosporin-
sensitive and -resistant strains, as well as extended-spectrum β-lactamase-producing 
strains; cincludes β-lactamase positive and negative strains; dall isolates with MIC . 0.5 
are F. mortiferum.
Abbreviations: MIC, minimum inhibitory concentration; MIC50, MIC for 50% of 
isolates; MIC90, MIC for 90% of isolates; MSSA, methicillin-susceptible Staphylococcus 
aureus; MRSA, methicillin-resistant S. aureus; CONS, coagulase-negative Staphylococcus; 
PSSP,  penicillin-sensitive  Streptococcus  pneumoniae;  PISP,  penicillin-intermediate   
S. pneumoniae; PRSP, penicillin-resistant S. pneumoniae; spp, species. 
  Gram-negative pathogens with favorable MICs include 
E. coli, Salmonella spp., K. oxytoca, K. pneumoniae, 
H. influenzae, and Moraxella catarrhalis.2 This spectrum has 
been confirmed against numerous pooled isolates in further 
in vitro testing.3,14–21 Of note there is no activity against 
P . aeruginosa or extended spectrum β-lactamase (ESBL) 
producing Gram-negative organisms.3 Ceftaroline has also 
demonstrated in vitro efficacy against a number of anaerobic 
bacteria, largely Gram-positive and β-lactamase-negative 
Gram-negative organisms.22,23 It has been tested in several 
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large samplings of pathogens causing CABP and ABSSSI 
with overall favorable results.24–28
One of the potential advantages of ceftaroline over other 
β-lactams is its activity against S. aureus isolates, including 
drug-resistant strains. In vitro testing against 152 strains 
of community-acquired MRSA from United States centers 
revealed the minimum inhibitory concentration required 
to inhibit the growth of 90% of organisms (MIC90) of 
ceftaroline to be 0.5 µg/mL, a 64-fold increase in potency 
over ceftriaxone. These strains all had Panton–Valentine 
leukocidin genes and 67.8% were USA300 strains.17 Activity 
of ceftaroline against MRSA and vancomycin-intermediate 
S. aureus has been confirmed in a hollow fiber model with 
ceftaroline demonstrating rapid bactericidal activity against 
these organisms.19 Further in vitro and in vivo testing has 
demonstrated activity against a broad range of S. aureus 
isolates including vancomycin-intermediate, vancomycin-
resistant, and daptomycin-nonsusceptible strains.29–32
Another therapeutic advantage of ceftaroline is its 
activity against a broad range of S. pneumoniae isolates,   
including penicillin-intermediate and -resistant strains. Ini-
tial in vitro testing demonstrated favorable MIC90 against 
penicillin-  sensitive, -intermediate, and -resistant strains 
with ceftaroline MICs of 0.06 µg/mL, 0.13 µg/mL, and 
0.25 µg/mL, respectively. These MICs are all favorable 
compared to ceftriaxone.2 Ceftaroline has demonstrated 
in vitro   efficacy against S. pneumoniae strains resistant to 
penicillin, amoxicillin, erythromycin, and cefotaxime,15,33 
showing superior in vitro activity to other β-lactams for 
cefotaxime-resistant strains.34 This superiority to ceftriaxone 
in resistant isolates has been demonstrated in vivo as well.35
Pharmacokinetics
Ceftaroline fosamil undergoes rapid dephosphorylation to the 
active drug after infusion. In a Phase I study of a single IV 
dose of ceftaroline to healthy subjects, a dose-proportional 
concentration was attained.36 In a 14 day IV dosing trial, the 
serum half-life of ceftaroline with 600 mg every 12-hour 
dosing was 2.6 hours with a maximal concentration of 
21 µg/mL.37 Dosing in patients with decreased renal function 
has demonstrated an increase in half-life (up to 4.6 hours 
in those with creatinine clearance averaging 38 mL/min), 
similar maximal concentration (31 µg/mL), but greatly 
increased area under the curve (120 hours*µg/mL versus 
68 hours*µg/mL in those with normal renal function).38 
Therefore a dose reduction to 400 mg every 12 hours is 
recommended for those with creatinine clearance between 
30–50 mL/min.39 There are no data for those with creatinine 
clearance less than 30 mL/min or those on hemodialysis. 
These pharmacokinetics have been confirmed with popula-
tion data from the ABSSSI and CABP studies.40,41 In a post-
hoc analysis of drug–drug interactions, ceftaroline levels 
were found to be modestly elevated in patients receiving 
CYP1A2 inhibitors, CYP3A4/5/7 inhibitors, and anionic 
drugs undergoing active renal secretion, but the effects of 
these increased levels are unclear.42
Safety and tolerability
Integrated safety data from the two FOCUS and two 
  CANVAS trials show comparable adverse event (AE) rates 
to the control groups.43,44 In the FOCUS studies, 47% of 
patients treated with ceftaroline had treatment-emergent 
AEs compared with 45.7% in the ceftriaxone group.   Serious 
AEs were 11.3% versus 11.7%, discontinuations 4.4% 
  versus 4.1%, and deaths 2.4% versus 2%. Only one death in 
each treatment group was felt by investigators to be related 
to study drug. In the ceftaroline group the most common 
AEs were diarrhea (4.2%), headache (3.4%), and insomnia 
(3.1%). There were more positive direct Coombs’ tests in 
the ceftaroline group (9.8% versus 4.5%), but no difference 
in rate of anemia (0.8% versus 0.4%). Results were similar 
in the CANVAS trials with treatment-emergent AEs occur-
ring in 44.7% of the ceftaroline group versus 47.5% of the 
vancomycin plus aztreonam group. Serious AEs were 4.3% 
versus 4.1%. The most common AEs in those receiving 
ceftaroline were nausea (5.9%), headache (5.2%), diarrhea 
(4.9%), and pruritis (3.5%). Similar to FOCUS data, in the 
CANVAS groups 11.5% of ceftaroline had positive direct 
Coombs’ tests complared with 4.3% in the comparator arm, 
but there was no hemolytic anemia in either group. Among 
all four studies there were only three cases of Clostridium 
difficile-associated diarrhea, all in CANVAS patients; two 
were in the ceftaroline group and one in the vancomycin 
plus aztreonam group.
The advantages and disadvantages 
of ceftaroline in line with current 
therapy strategies
The largest of ceftaroline’s potential advantages over other 
agents, particularly other β-lactams, is its activity against 
MRSA, a pathogen that has had a recent steady increase in 
incidence45 as well as in antimicrobial resistance.46 Overall 
cases of MRSA infection doubled from 1999–2005 from 
127,036 hospital admissions in 1999 to 278,203 in 2005. 
MRSA has increased from 43% of S. aureus infection to 
58% over this time period.47 Based on active surveillance at 
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several sites, in 2005 there were an estimated 94,360 cases 
of invasive MRSA infection in the United States with 18,650 
deaths.48 A majority (58.4%) of cases were community-onset 
in nature.
In the FOCUS studies, ceftaroline was compared head-
to-head with ceftriaxone, which is a preferred agent in the 
Infectious Diseases Society of America (IDSA)/American 
Thoracic Society guidelines for treatment of CABP (along 
with a macrolide for coverage of atypical organisms).49 In 
these noninferiority trials, ceftaroline was shown to be within 
the defined −10% performance range of ceftriaxone overall, 
and therefore noninferior. While ceftaroline did have numeric 
superiority in several populations including those in most of 
the defined study groups and subgroups,8 given the design of 
these trials to test noninferiority and not superiority, ceftaro-
line cannot be called superior without further trials.
While not a traditional pathogen in CABP, MRSA is 
being recognized more and more frequently as a cause of 
severe pneumonia in otherwise healthy patients, as well 
as following influenza infection.50–53 Ceftaroline has a 
demonstrated bactericidal effect in MRSA pneumonia in 
animal studies. Early models demonstrated a colony count 
decrease of more than 99.9% in neutropenic mice with 
MRSA pneumonia when treatment with ceftaroline was 
started one day after infection compared with no significant 
change in colony counts with similar timing of linezolid or 
vancomycin.2 Of note, all three agents were equally effec-
tive when started only 2 hours after infection, but as MRSA 
is not a commonly thought of pathogen in CABP, directed 
anti-MRSA therapy is usually not initiated until following 
recovery of the organism. Further studies of ceftaroline for 
MRSA pneumonia are needed.
For ABSSSI, the current IDSA guidelines focus on 
Gram-positive coverage for cellulitis but specifically mention 
the growing problem of resistant S. aureus and S. pyogenes 
isolates in the selection of empiric therapy.54 Indeed, in studies 
of microbiology of ABSSSI, MRSA is a predominant isolate. 
A prospective evaluation of patients with ABSSSI in an emer-
gency department in northern   California in 2003–2004 revealed 
over half to be infected with S. aureus; 75% of their staphy-
lococcal isolates were MRSA.55 In Atlanta in 2003, 72% 
of S. aureus isolates were MRSA; a majority of these were 
USA300 strains.56 A 2008 prospective multicenter evaluation 
of purulent ABSSSI revealed 75% of these infections to be 
due to S. aureus, of which 79% were MRSA. 96% of these 
isolates were USA300.57 As in the FOCUS  trials, the CANVAS 
trials were designed to demonstrate noninferiority, an aim at 
which they were successful.6,7,10 There is statistically significant 
improved outcome for   ceftaroline over vancomycin plus 
aztreonam for ABSSSI in the United States study sites in the 
CANVAS 1 trial, but the trial had a small number of patients 
and the study was not designed for this particular outcome. 
Further testing particularly with USA300 infection is neces-
sary. With Gram-negative-only infections, ceftaroline was 
statistically inferior with a cure rate of 85.3% versus 100%, 
but again the study had small numbers and this outcome was 
outside the study design.
Ceftaroline has had limited clinical use to demonstrate 
development of antimicrobial resistance, but in vitro serial 
passage studies have shown limited resistance induced in 
multiple Gram-positive and Gram-negative pathogens.58 
In this study no strains of S. pneumoniae or S. aureus 
  demonstrated increased ceftaroline MIC after 50 daily serial 
passages. There was rare inducible resistance in H. influenzae 
and E. faecalis. There are no reports on development of 
resistance in the FOCUS and CANVAS trials.
Ceftaroline may eventually have a role in infections 
other than CABP and ABSSSI as well. Jacqueline et al 
initially demonstrated rapid bactericidal activity in vivo in 
a rabbit endocarditis model of infection due to MRSA and 
vancomycin-intermediate S. aureus (VISA), with comparable 
activity to vancomycin in MRSA infection and improved 
vegetation sterilization relative to vancomycin in VISA as 
well as favorable performance compared to linezolid in both 
strains.59 More recently ceftaroline was compared with dapto-
mycin and tigecycline in MSSA, MRSA, and glycopeptide-
intermediate S. aureus (GISA). Ceftaroline was superior 
to tigecycline and equivalent to daptomycin in vegetation 
sterilization for all isolates.30 Another animal study with 
ampicillin-sensitive E. faecalis endocarditis demonstrated 
improved bacterial killing and vegetation sterilization over 
vancomycin and linezolid in vancomycin-susceptible and 
vancomycin-resistant strains.60 Current guidelines recom-
mend ampicillin or penicillin plus gentamicin for these 
infections.61 These animal endocarditis studies may provide 
the basis for further clinical evaluation, though so far, data 
in humans are lacking.
Ceftaroline has also demonstrated superiority to van-
comycin and comparableness to linezolid in treatment of 
rabbit osteomyelitis due to MRSA and GISA.62 Finally, 
ceftaroline has been shown to be superior to ceftriaxone in 
meningitis in rabbits due to penicillin-sensitive S. pneumoniae 
and a combination of ceftriaxone and vancomycin in 
penicillin-resistant S. pneumoniae.63 Current guidelines recom-
mend the combination of vancomycin and a third-generation 
cephalosporin for initial therapy of bacterial meningitis due 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
153
Ceftaroline for pneumonia and skin infectionTherapeutics and Clinical Risk Management 2012:8
to S. pneumoniae64 Ceftaroline monotherapy may be further 
investigated for this application as well, though again, human 
data remain lacking to date.
One potential disadvantage of ceftaroline compared 
with other broad spectrum antibacterial agents is its lack 
of coverage of Gram-negative organisms, particularly those 
producing β-lactamases including AmpC, extended-spectrum 
β-lactamase (ESBL), and K. pneumoniae carbapenemase 
(KPC).19 Ceftaroline has been combined with a novel 
β-lactamase inhibitor, NXL104, with excellent in vitro sus-
ceptibility data for bacteria with these β-lactamases. This 
combination when tested in vivo demonstrated bactericidal 
activity in a mouse thigh infection model.65 Further phar-
macodynamic modeling is being undertaken for the optimal 
dosing combination of these two agents.66 This promising 
combination also bears further investigation for treatment 
of these very challenging infections.
Conclusion and place in therapy
Ceftaroline has a promising role in the future of infectious 
diseases. It has been labeled the first new drug in the IDSA’s 
“10 × ‘20” initiative to have ten new antibiotics released by 
the year 2020.67 However, it has several obstacles to overcome 
prior to routine use over current guideline recommendations. 
At present it is approved only for CABP and ABSSSI and has 
demonstrated only noninferiority as opposed to superiority to 
its comparators. The lack of clinical trial data in patients with 
MRSA pneumonia and bacteremia separate from ABSSSI and 
CABP in particular make it difficult to recommend ceftaroline 
over alternative therapies. Until there is more significant clini-
cal experience, it can at least be counted among the dwindling 
array of options clinicians have to fight these increasingly 
resistant routine infections. Ceftaroline’s potential for treat-
ment of invasive infections due to MRSA and other resistant 
organisms is tantalizing and bears more investigation. It is 
hoped further clinical studies will illuminate the question mark 
looming over this otherwise promising new drug.
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